Preparation method of injectable temperature-sensitive hydrogel loaded with alpha-mangostin
By preparing a thermosensitive hydrogel loaded with α-dextrin, the problems of low bioavailability of α-dextrin and poor antibacterial effect of chitosan were solved, achieving effective elimination of Gram bacteria and wound healing, enhancing the therapeutic effect and simplifying the preparation process.
Patent Information
- Application Number
- CN202411456096.2
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-10-18
- Publication Date
- 2024-11-19
AI Technical Summary
In existing technologies, α-dextrin has low bioavailability and poor solubility, chitosan has poor antibacterial effects and is difficult to retain for a long time, and existing antibiotics have side effects in treating chronic wound infections. How to achieve effective anti-inflammatory and sterilization and promote wound healing while avoiding the overuse of antibiotics is an urgent problem to be solved.
A thermosensitive hydrogel loaded with α-dextrin was prepared by using chitosan and poloxamer to form a thermosensitive gel that encapsulates α-dextrin, thereby achieving sustained drug release, enhancing antibacterial properties, and improving biocompatibility. The preparation process employed physical stirring and centrifugal stilling methods.
It enhances therapeutic efficacy, improves biocompatibility, reduces side effects, expands the drug's applicability, simplifies the preparation process, improves stability and bioavailability, achieves the elimination of Gram-negative and Gram-positive bacteria, and promotes wound healing.
Smart Images

Figure CN118975978A_ABST
Abstract
Description
Technical Field
[0001] The invention relates to the technical field of biomedicine, and in particular to a method for preparing an injectable thermosensitive hydrogel loaded with alpha-mangostin. Background Art
[0002] The skin can protect the human body from various external stimuli. When it is severely damaged, it loses its protective function, allowing microorganisms to invade, destroy, proliferate, and multiply, making it difficult for wounds to heal. The healing site will have an inflammatory reaction, such as redness, swelling, nodules, hematomas, and effusion. According to relevant data, the global chronic wound infection rate is 78.2%. At present, the treatment of bacterial infections mainly uses antibiotics. With the deepening of scientific understanding, we have a deeper understanding of the side effects of antibiotics. How to further achieve the effect of anti-inflammatory and sterilization without the abuse of antibiotics is an important issue that needs to be solved urgently. Plant-derived substances have always attracted much attention. As natural antibacterial compounds, they are expected to become an alternative strategy to antibiotics. α-Mangostin is a natural product of xanthone isolated from mangosteen husk. It has good biosafety and excellent antibacterial properties. The MIC level of α-M against various strains is comparable to that of vancomycin. However, the bioavailability of α-M is extremely low and the solubility is extremely poor, which is an urgent problem to be solved.
[0003] Chitosan is the deacetylated product of chitin and the only alkaline aminopolysaccharide among natural polysaccharides. It is widely used in the field of biomedical research due to its good biocompatibility. However, chitosan has poor antibacterial effect and is difficult to remain in the human body for a long time, which greatly limits its antibacterial ability.
[0004] As a classic thermosensitive copolymer, poloxamer has been listed as a pharmaceutical excipient by the US Food and Drug Administration. Poloxamer is composed of hydrophobic chains, which are composed of hydrophobic chains of polypropylene oxide (PPO) and hydrophilic chains of polyethylene oxide (PEO), forming a triblock structure of PEO-PPO-PEO. Due to its good biocompatibility and thermosensitivity, the in situ gel formation of poloxamer has been widely studied. Due to the hydrogen bonding between poloxamer and water molecules, it is liquid at low temperatures. The hydrogen bonds are unstable when heated. The self-assembly of poloxamer 407 molecular chains enables them to be arranged into micelles with hydrophobic PPO cores and hydrophilic PEO tails at low critical solution temperatures. At a certain concentration of poloxamer, liquid poloxamer transforms into gel at higher temperatures due to the orderly stacking and entanglement of micelles. Summary of the invention
[0005] The technical solution of the present invention to solve the above technical problem is to provide a method for preparing an injectable thermosensitive hydrogel loaded with α-mangostin, comprising the following steps: Chitosan was dissolved in acetic acid solution and stirred with a magnetic stirrer at room temperature; After the chitosan powder is completely dissolved, add glycerol; Poloxamer 407 and poloxamer 188 were added and stirred at room temperature to make the poloxamer powder evenly distributed in the chitosan hydrogel; Place in a 4℃ refrigerator and let stand; α-mangostin is placed in a centrifuge tube, and the hydrogel is injected into the centrifuge tube using a syringe. The drug is wrapped by a physical stirring method and then centrifuged to a standstill to prepare a chitosan-based drug-loaded thermosensitive hydrogel.
[0006] Furthermore, in the step of dissolving chitosan in acetic acid solution and stirring with a magnetic stirrer at room temperature, the mass of chitosan required is 0.13g-0.15g; the concentration of the acetic acid solution is 1% and the amount is 5mL-15ml; and the magnetic stirring time is 3-5h.
[0007] Furthermore, in the step of adding glycerol after the chitosan powder is completely dissolved, the amount of glycerol added is 50uL-70uL.
[0008] Furthermore, in the step of adding poloxamer 407 and poloxamer 188 and stirring at room temperature to uniformly distribute the poloxamer powder in the chitosan hydrogel, the mass of poloxamer 407 is 1.5 g; the mass of poloxamer 188 is 0.8 g-1.4 g; and the magnetic stirring time is 2 min-4 min.
[0009] Furthermore, the step of placing the mixture in a 4° C. refrigerator for a standing time of 40 h to 72 h.
[0010] Furthermore, in the step of placing α-mangostin in a centrifuge tube, injecting the hydrogel therein with a syringe, encapsulating the drug by a physical stirring method, and then centrifuging and standing to obtain the chitosan-based drug-loaded thermosensitive hydrogel, the mass of α-mangostin is 10 mg-50 mg; the amount of the injected hydrogel is 1 mL; the centrifugal speed is 2000 r / min, the time is 5 min-30 min; and the standing time is 12 h.
[0011] Compared with the prior art, the technical solution of the present invention has the following beneficial effects: 1. Enhanced therapeutic effects: In the medical field, the present invention may enhance the therapeutic effect through more effective drug delivery or treatment methods.
[0012] 2. Improved biocompatibility: The present invention may improve the compatibility of thermosensitive hydrogels with human tissues and reduce immune responses or other side effects.
[0013] 3. Environmentally friendly: The present invention may be more environmentally friendly, reduce waste generation, and the materials used in preparing the thermosensitive hydrogel have no pollution risk to the environment.
[0014] 4. Easy operation: The present invention may simplify the preparation process of the thermosensitive hydrogel, making the preparation process easier and greatly shortening the preparation time.
[0015] 5. Expanded scope of use: The invention may expand the applicable field of the drug, enabling it to be used in a wider market.
[0016] 6. Reduce side effects: The present invention may reduce side effects by optimizing drug formulation or delivery method.
[0017] 7. Improved stability: The present invention may improve the chemical or physical stability of the product and enable long-term storage at room temperature.
[0018] 8. The present invention uses plant active substance α-M to replace existing antibiotics, mixes chitosan to improve the antibacterial properties of chitosan, and gives chitosan hydrogel thermosensitivity by adding thermosensitive agent poloxamer, so that it becomes a gel in the body after injection, realizes the sustained release of drugs, thereby improving the bioavailability of α-M and solving its insoluble problem, and realizes the elimination of Gram-negative bacteria and Gram-positive bacteria. The antibacterial and wound healing thermosensitive hydrogel is simple to prepare and has high biocompatibility, and can be widely used in the field of biomedicine. BRIEF DESCRIPTION OF THE DRAWINGS
[0019] In order to more clearly illustrate the embodiments of the present invention or the technical solutions in the prior art, the drawings required for use in the embodiments or the description of the prior art will be briefly introduced below. Obviously, the drawings described below are only some embodiments of the present invention. For ordinary technicians in this field, other drawings can be obtained based on the structures shown in these drawings without paying creative work.
[0020] Figure 1 It is a schematic flow chart of the preparation method of the injectable thermosensitive hydrogel loaded with α-mangostin according to the present invention; Figure 2 This is a SEM image of the injectable thermosensitive hydrogel of the present invention; Figure 3 The present invention is an image of the fluidity of the injectable thermosensitive hydrogel; Figure 4 The present invention is a swelling image of an injectable thermosensitive hydrogel; Figure 5 The present invention is a degradation image of the injectable thermosensitive hydrogel; Figure 6 The drug release image of the injectable thermosensitive hydrogel of the present invention is shown; Figure 7The inhibition zone image of the injectable thermosensitive hydrogel of the present invention (Gram-positive S. aureus); Figure 8 The images of inhibition zones of the injectable thermosensitive hydrogel of the present invention at different drug loading concentrations (Gram-positive S. aureus); Fig. 9 This is an antibacterial rate test image of the injectable thermosensitive hydrogel of the present invention; Fig.10 The present invention is a wound healing image of mice (Gram-positive S. aureus); Fig.11 The present invention is an image of wound healing rate in mice (Gram-positive S. aureus); Fig.12 The present invention is an MTT image; Fig.13 The present invention is a hemolysis rate image; Fig.14 The injectability image of the injectable thermosensitive hydrogel of the present invention is shown; Fig.15 The inhibition zone image (Gram-negative E. coli) of the injectable thermosensitive hydrogel of the present invention is shown; Fig.16 The images of inhibition zones (Gram-negative E. coli) of different drug loading concentrations of the injectable thermosensitive hydrogel of the present invention are shown; Fig.17 The present invention is a mouse wound healing image (Gram-negative E. coli); Fig.18 The present invention shows an image of wound healing rate in mice (Gram-negative E. coli). DETAILED DESCRIPTION
[0021] The present invention proposes a method for preparing an injectable thermosensitive hydrogel loaded with α-mangostin, aiming to design a method for preparing an injectable thermosensitive hydrogel loaded with α-mangostin, achieve a sustained release effect on the drug, thereby improving the bioavailability of α-M, solving its insoluble problem, and achieving the disinfection of Gram-negative bacteria and Gram-positive bacteria.
[0022] The preparation method of the injectable thermosensitive hydrogel loaded with α-mangostin proposed by the present invention will be described in the following specific examples: In the technical solution of this embodiment, Figure 1 As shown, a method for preparing an injectable thermosensitive hydrogel loaded with α-mangostin comprises the following steps: S10: dissolving chitosan in acetic acid solution and stirring with a magnetic stirrer at room temperature; S20: After the chitosan powder is completely dissolved, glycerol is added; S30: adding poloxamer 407 and poloxamer 188, and stirring at room temperature to make the poloxamer powder evenly distributed in the chitosan hydrogel; S40: Place in a 4°C refrigerator and let stand; S50: α-mangostin is placed in a centrifuge tube, and the hydrogel is injected into the tube using a syringe. The drug is wrapped by physical stirring and then centrifuged to obtain a chitosan-based drug-loaded thermosensitive hydrogel.
[0023] Furthermore, in the step of dissolving chitosan in acetic acid solution and stirring with a magnetic stirrer at room temperature, the mass of chitosan required is 0.13g-0.15g; the concentration of the acetic acid solution is 1% and the amount is 5mL-15ml; and the magnetic stirring time is 3-5h.
[0024] Furthermore, in the step of adding glycerol after the chitosan powder is completely dissolved, the amount of glycerol added is 50uL-70uL.
[0025] Furthermore, in the step of adding poloxamer 407 and poloxamer 188 and stirring at room temperature to uniformly distribute the poloxamer powder in the chitosan hydrogel, the mass of poloxamer 407 is 1.5 g; the mass of poloxamer 188 is 0.8 g-1.4 g; and the magnetic stirring time is 2 min-4 min.
[0026] Furthermore, the step of placing the mixture in a 4° C. refrigerator for a standing time of 40 h to 72 h.
[0027] Furthermore, in the step of placing α-mangostin in a centrifuge tube, injecting the hydrogel therein with a syringe, encapsulating the drug by a physical stirring method, and then centrifuging and standing to obtain the chitosan-based drug-loaded thermosensitive hydrogel, the mass of α-mangostin is 10 mg-50 mg; the amount of the injected hydrogel is 1 mL; the centrifugal speed is 2000 r / min, the time is 5 min-30 min; and the standing time is 12 h.
[0028] Example 1: A method for preparing an injectable drug-loaded chitosan thermosensitive hydrogel, comprising the following steps: 0.14 g chitosan was dissolved in 1% acetic acid solution and stirred with a magnetic stirrer at room temperature for 4 h; After the chitosan powder is completely dissolved, add 60uL of glycerol; Add 1.5 g of poloxamer 407 and 0.8 g of poloxamer 188, and stir at room temperature for 2 min to evenly distribute the poloxamer powder in the chitosan hydrogel; Place in a 4℃ refrigerator for 48h; 30 mg of α-mangostin was placed in a centrifuge tube, and the hydrogel was injected into the tube using a 1 mL syringe. The drug was wrapped by physical stirring and then centrifuged at 2000 r / min for 10 min to obtain a chitosan-based drug-loaded thermosensitive hydrogel.
[0029] like Figure 2 Shown is the SEM image of the prepared chitosan-based drug-loaded thermosensitive hydrogel; like Figure 3 , Fig.14 The figure shows the temperature sensitivity and injectability of the prepared chitosan-based drug-loaded thermosensitive hydrogel. The mass of the hydrogel increased due to water absorption after 2 hours in a constant temperature shaker at 34°C and 100r / m. The mass gradually decreased after 2 hours until it was completely soluble in the PBS solution after 11.5 hours, indicating that the hydrogel gradually degraded in the PBS solution, proving the in vitro degradability of the CPP hydrogel. The freeze-dried gel hydrogel reached the highest swelling rate of 134.69% after 10 minutes. The CPP hydrogel is: C is CS represents chitosan PP is Poloxamer 407 and Poloxamer 188 represents the thermosensitive agents Poloxamer 407 and 188 Swelling rate test of chitosan-based drug-loaded thermosensitive hydrogel: The water absorption properties of the hydrogels were studied by mass analysis. 50 mg of freeze-dried hydrogel blocks were added to 30 mL of phosphate buffered saline (PBS, pH 7.4) and soaked at 37 °C for a period of time. Water was wiped off the surface of the hydrogel with filter paper, and the mass of the hydrogel was weighed at different times to calculate the swelling rate.
[0030] The calculation formula of the swelling ratio is: swelling ratio (%) = (mt - m0 ) / m0×100%, where mt and m0 are the masses of the hydrogel at time t and the initial mass, respectively.
[0031] like Figure 4 As shown in the figure, the hydrogel increased in mass due to water absorption in a constant temperature shaker at 34°C and 100 r / m for 2 hours, and then gradually decreased in mass until it was completely dissolved in PBS solution after 11.5 hours, indicating that the hydrogel gradually degraded in the PBS solution, proving the in vitro degradability of the CPP hydrogel. The freeze-dried hydrogel reached the highest swelling rate of 134.69% after 10 minutes.
[0032] Degradation performance test of chitosan-based drug-loaded thermosensitive hydrogel: A certain volume of hydrogel was injected into a 50 mL centrifuge tube, placed in a 34°C constant temperature water bath to allow the hydrogel to gel, then slowly injected with 30 mL of PBS, and then placed in a 37°C 100 r / min constant temperature shaker to observe its morphological changes until it is completely dissolved, and the time was recorded.
[0033] like Figure 5 As shown, the mass of the hydrogel increased due to water absorption after 2 hours in a constant temperature shaker at 34°C and 100 r / m, and then gradually decreased after 2 hours until it was completely dissolved in the PBS solution after 11.5 hours, indicating that the hydrogel was gradually degraded in the PBS solution, proving the in vitro degradability of the CPP hydrogel.
[0034] Drug release test of chitosan-based thermosensitive hydrogel: 1 mL of hydrogel was injected into a 50 mL centrifuge tube, placed in a 34°C constant temperature water bath to allow the hydrogel to gel, then 30 mL of PBS was slowly injected, and then placed in a 37°C 100 r / min constant temperature shaker. 3 mL of solution was taken out at a specific time point, and the absorbance was measured at 280 nm by a UV spectrophotometer, and the drug release amount was calculated to draw a drug release curve.
[0035] like Figure 6 As shown in the figure, the release of α-M from the chitosan-based thermosensitive hydrogel increased significantly within eight hours, with a cumulative α-M release of about 57.3%. The release reached 61.5% at 11.5 hours. This shows that once the gel is immersed in the medium, the α-M contained in the hydrogel is released.
[0036] Antibacterial test of chitosan-based drug-loaded thermosensitive hydrogel: 100 μL of bacterial solution (10 8 CFU / mL) was evenly spread on the agar plate, and a sterile paper sheet (6.0 mm diameter, autoclaved) was immersed in the hydrogel and then placed on the bacterial plate. After culturing at 37°C for 24 hours, the diameter of the outer ring of the inhibition zone was measured with a ruler. 150uL of bacterial solution (10 8 CFU / mL) and 50uL of hydrogels with different α-M loading amounts were added into a 96-well plate and placed in a 37°C incubator for 24 hours. The OD value was measured at 490nm and the inhibition rate was calculated.
[0037] like Figure 7 , Fig.15 As shown, the hydrogel's antibacterial activity against Gram-negative E. coli and Gram-positive S. aureus was tested by the inhibition zone method. The hydrogel's antibacterial activity against Gram-negative E. coli and Gram-positive S. aureus was studied. The hydrogel's inhibition diameter against Staphylococcus aureus was 0.51 cm. The inhibition diameter against Escherichia coli was almost 0. The hydrogel's inhibition ring radius against Escherichia coli was relatively small, and it had a strong inhibitory effect on Staphylococcus aureus.
[0038] like Figure 8 , Fig.16As shown, the antibacterial diameter of the hydrogel with different drug loading concentrations. It can be seen from the figure that the antibacterial diameter increases with the increase of drug loading. When the drug loading concentration is 50 mg, the antibacterial diameter against Staphylococcus aureus and Escherichia coli reaches the maximum value, which is 5.38 cm and 3.78 cm respectively.
[0039] like Fig. 9 As shown in the figure, the inhibition rate test shows that after incubation at 37°C for 12 h, the inhibition rate of bacteria increases with the increase of drug loading concentration. When the drug loading reaches 50 mg, the inhibition rate of the hydrogel against S. aureus is 97.44%, and the inhibition rate against E. coli is 77.2%. Since the bacteria are in the logarithmic growth phase and have strong activity when the detection time is 12 h, the hydrogel has a strong inhibitory ability against bacteria.
[0040] Wound healing test of chitosan-based drug-loaded thermosensitive hydrogel: The mice were randomly divided into 12 groups, 5 in each group. The groups were equally divided, and the Staphylococcus aureus and Escherichia coli infection models were established after depilation of the back of each group of mice for anesthesia. Three groups in each model received different treatments, including a control group, a blank hydrogel group, and a drug-loaded hydrogel group. After intraperitoneal injection of anesthesia and shaving, the entire skin layer was removed with surgical scissors. 100 μL of a concentration of 10 8 CFU / mL of Staphylococcus aureus and Escherichia coli solutions were added to the wound surface to establish a wound model. 48 hours after infection, 100uL of PBS solution, blank hydrogel, and drug-loaded hydrogel were injected around the wound. Subsequently, the wound changes of mice on different days after treatment were recorded using a mobile phone on days 1, 5, 9, and 13, and the size of the wound was quantified.
[0041] It can be understood that the mice are 6-8 week old female Kunming mice (KM mice) (provided by Yisi Experimental Animal Technology Co., Ltd.).
[0042] like Fig.10 , Fig.17 The following are the wound healing images of mice infected with various bacterial strains at 1, 5, 9, and 13 days. During the entire wound healing process, the drug-loaded hydrogel group had better therapeutic effects on various bacterial infection models than other groups, and the wounds infected with various bacterial strains were almost completely healed after 13 days of treatment.
[0043] like Fig.11 , Fig.18 The following table shows the healing rate of small wounds in each bacterial model. The wound infected by Staphylococcus aureus was almost completely healed after 13 days of treatment, while the remaining healing area of the blank control group was 4.43%. The remaining wound area of Escherichia coli was 6.01% after 13 days of treatment, but the remaining wound healing area of the control group was 49.93%.
[0044] Safety testing of chitosan-based drug-loaded thermosensitive hydrogel: The cells in the logarithmic phase that were cultured the day before were digested, centrifuged, and counted. 100 μL of 3k-7k / well cells were inoculated on a 96-well plate and cultured for 24 hours at 37°C, 5% CO2, and 90% humidity. The cell growth state and density were observed under a microscope, and the wells with good growth state, uniform cell distribution and density were taken for the experiment. Weigh 25 mg of freeze-dried composite hydrogel and sterilize it under ultraviolet light for 30 minutes, and add 1 mL of RPMI-1640 culture medium to co-culture for 24 hours to obtain hydrogel extracts. Three replicate wells of the extracts obtained at each time were added to a 96-well plate and cultured for 12 hours at 37°C, 5% CO2, and 90% humidity. MTT was thawed and centrifuged at room temperature before use, and the cell growth state was detected with an inverted microscope, and the wells with good growth state, uniform cell distribution and density were taken with 4X / 10X to take pictures and record. 10 μL of MTT solution was added to each well to make a final concentration of 0.5 mg / mL. Incubate for 4 hours at 37°C, 5% CO2, 90% humidity. Carefully aspirate all the supernatant in the wells to prevent the monolayer from rupturing. Place the plate on an oscillator at 300 rpm / min for 10 minutes to dissolve the formazan completely. Measure the absorbance at 570 nm using an ELISA reader.
[0045] Take blood from healthy mice, put it into a conical bottle containing glass beads and shake it for 10 minutes, or stir the blood with a glass rod to remove fibrinogen and make it into defibrinated blood to prepare 4% red blood cell suspension. Add about 10 times the amount of 0.9% sodium chloride solution, shake well, centrifuge at 1000-1500 revolutions per minute for 15 minutes, remove the supernatant, and wash the precipitated red blood cells with 0.9% sodium chloride solution 2-3 times according to the above method until the supernatant is no longer red. The obtained red blood cells are made into a 4% suspension with 0.9% sodium chloride solution for test. Prepare sample and positive control solutions. The sample working solution concentrations were set to 256μg / mL, 128 μg / mL, 64μg / mL, 32μg / mL, 16μg / mL, 8μg / mL, 4μg / mL, 2μg / mL, 1μg / mL, 0.5μg / mL, and 0.25μg / mL. The positive control (Triton-X-100) content ratios were set to 1%, 0.5%, 0.25%, 0.125%, 0.062%, 0.031%, 0.016%, 0.008%, 0.004%, 0.002%, and 0.001%. Dissolve the sample to be tested to a stock solution concentration of 51.2mg / mL, add 198μL PBS to A1-J1 of a 96-well plate, add 196μL PBS to well H1, and add 100μL PBS to each of the remaining wells. Add 2 μL of sample stock solution to the 96-well plate A1-J1 (the concentration of A1-J1 wells is 5.12 mg / mL at this time) and mix well. Then aspirate 100 μL from A1-H1 well and add it to A2-J2 wells and mix well. Aspirate 100 μL from A2-J2 wells and add it to A3-J3 wells and mix well.
[0046] like Fig.12 Shown is the MTT image of chitosan-based drug-loaded thermosensitive hydrogel. The survival rate of 3T3 cells was 87% at 24 h.
[0047] like Fig.13 As shown, the hemolysis rate image of chitosan-based drug-loaded thermosensitive hydrogel, where the hemolysis rate threshold of biological materials in contact with blood is usually 5%. When the concentration of the hydrogel is 10 mg / mL, the hemolysis rate is 3.2%.
[0048] The above is only a preferred specific embodiment of the present invention, but the protection scope of the present invention is not limited thereto. Any changes or substitutions that can be easily thought of by a person skilled in the art within the technical scope disclosed by the present invention should be included in the protection scope of the present invention. Therefore, the protection scope of the present invention should be based on the protection scope of the claims.
Claims
1. A method for preparing an injectable thermosensitive hydrogel loaded with α-mangostin, characterized in that: The following steps are involved: Step 10: Dissolve chitosan in acetic acid solution and stir using a magnetic stirrer at room temperature; Step 20: After the chitosan powder is completely dissolved, add glycerol; Step 30: Add poloxamer 407 and poloxamer 188, and stir at room temperature to make the poloxamer powder evenly distributed in the chitosan hydrogel; Step 40: Place in a 4°C refrigerator and let stand; Step 50: Place α-mangostin in a centrifuge tube, inject the hydrogel into the centrifuge tube using a syringe, encapsulate the drug by physical stirring, and then centrifuge to obtain a chitosan-based drug-loaded thermosensitive hydrogel.
2. The method for preparing the injectable thermosensitive hydrogel loaded with α-mangostin according to claim 1, characterized in that: In the step of dissolving chitosan in acetic acid solution and stirring with a magnetic stirrer at room temperature, the mass of chitosan required is 0.13g-0.15g; the concentration of the acetic acid solution is 1% and the amount is 5mL-15ml; and the magnetic stirring time is 3-5h.
3. The method for preparing the injectable thermosensitive hydrogel loaded with α-mangostin according to claim 1, characterized in that: In the step of adding glycerol after the chitosan powder is completely dissolved, the amount of glycerol added is 50uL-70uL.
4. The method for preparing the injectable thermosensitive hydrogel loaded with α-mangostin according to claim 1, characterized in that: In the step of adding poloxamer 407 and poloxamer 188 and stirring at room temperature to uniformly distribute the poloxamer powder in the chitosan hydrogel, the mass of poloxamer 407 is 1.5 g; the mass of poloxamer 188 is 0.8 g-1.4 g; and the magnetic stirring time is 2 min-4 min.
5. The method for preparing the injectable thermosensitive hydrogel loaded with α-mangostin according to claim 1, characterized in that: The step of placing the mixture in a 4° C. refrigerator for a standing time is 40 h to 72 h.
6. The method for preparing the injectable thermosensitive hydrogel loaded with α-mangostin according to claim 1, characterized in that: In the steps of placing α-mangostin in a centrifuge tube, injecting the hydrogel therein with a syringe, encapsulating the drug by a physical stirring method, and then centrifuging and standing to prepare a chitosan-based drug-loaded thermosensitive hydrogel, the mass of α-mangostin is 10 mg-50 mg; the amount of the injected hydrogel is 1 mL; the centrifugal speed is 2000 r / min, the time is 5 min-30 min; and the standing time is 12 h.
Citation Information
Patent Citations
Thermosensitive in-situ gel preparation for norcantharidin injection and preparation method and application of thermosensitive in-situ gel preparation
CN105902485A
Use of mangosteen fruit skin extract in treatment of skin diseases
CN106361784A
Preparation method of temperature-sensitive type chitosan-based anti-acne aquagel for cosmetics
CN108354854A
Teriparatide sustained release gel injection solution and preparation method therefor
WO2021036058A1
Cited By
Preparation method and application of drug-loaded hydrogel
CN119454577A
